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Uterine sarcomas are a rare heterogeneous group of tumors 
of mesenchymal origin, accounting for approximately 8% 
of uterine malignancies. They comprise leiomyosarcoma, 
endometrial stromal sarcoma, undifferentiated endometrial 
sarcoma, and adenosarcoma. Compared with the more com-
mon endometrial carcinomas, uterine sarcomas behave more 
aggressively and are associated with a poorer prognosis. Due 
to their distinct clinical and biological behavior, the Interna-
tional Federation of Gynecology and Obstetrics introduced a 
new staging system for uterine sarcomas in 2009, categoriz-
ing uterine carcinosarcoma as a variant of endometrial carci-
noma, rather than a pure sarcoma. Magnetic resonance im-
aging (MRI) has a developing role in the assessment of these 
malignancies. Features such as tumor localization, irregular 
or nodular margins, necrosis, rapid growth, intense contrast 
enhancement, and restriction at diffusion-weighted imaging 
can suggest the diagnosis and help differentiate from more 
common leiomyomas and endometrial carcinoma. MRI is 
therefore extremely useful in preoperative detection and 
staging and, consequently, in determination of appropriate 
management. This pictorial review aims to discuss the clinical 
features of uterine sarcomas, as well as their most common 
appearances and distinct characteristics in MRI.
U terine sarcomas are a rare heterogeneous group of tumors of mes-enchymal origin, accounting for approximately 8% of uterine malignancies (1), although they were thought to represent only 
2% to 3% of all uterine tumors in the past (2). This increased incidence 
may be the result of improved diagnosis, as well as a true increase in an 
ageing population (1).
These malignancies may originate from the smooth muscle in myo-
metrium (leiomyosarcoma), from the endometrial stroma (endometrial 
stromal sarcoma [ESS] and undifferentiated endometrial sarcoma [UES]) 
or both (adenosarcoma) (3). According to the Gynecologic Oncology 
Group, uterine sarcomas can be classified into two categories: nonep-
ithelial and mixed epithelial-nonepithelial, depending on the type of 
cancerous cell and its presumed tissue of origin (4).
The clinical presentation of uterine sarcomas is nonspecific and de-
pendent of histologic subtype. Classically, they present as a rapidly 
growing pelvic mass, which may be accompanied by vaginal bleeding 
and abdominal or pelvic pain (1, 5).
Leiomyosarcoma is the most common histological variant of uterine 
sarcomas and is considered an aggressive tumor associated with poor 
prognosis, with a five-year survival rate ranging from 18.8% to 68%. ESS 
is relatively indolent, associated with long-term survival, but character-
ized by late recurrences (14%–60% of women). In contrast, UES has a 
very aggressive behavior and poor prognosis, with a five-year survival 
rate of 25%–55%. Adenosarcomas are rare mixed tumors (glandular and 
mesenchymal origin) with relatively low malignant potential and slow-
growth pattern, with a five-year survival rate above 80% (6).
The recognition of their distinct clinical and biological behavior when 
compared to endometrial carcinoma, which tend to behave more ag-
gressively and are associated with a poorer prognosis, led the Interna-
tional Federation of Gynecology and Obstetrics (FIGO) to develop a 
new staging system for uterine sarcomas in 2009 (Tables 1 and 2). One 
important feature of the new staging system is that carcinosarcoma (for-
merly referred to as “malignant mixed Müllerian tumor”) is no longer 
considered as part of uterine sarcomas, being classified as a dedifferenti-
ated or metaplastic form of endometrial carcinoma (7).
The distinction among different subtypes of uterine sarcomas and 
other uterine tumors (especially leiomyoma and endometrial carcino-
ma) cannot be made on clinical grounds. Therefore, imaging, particular-
ly MRI, has a developing role in the assessment of these malignancies, 
being useful in the evaluation of pelvic masses at presentation, adequate 
staging (assessment of invasion depth, spread to adjacent organs and 
lymph nodes), and consequently, determination of appropriate man-
agement.
From the Department of Radiology (P.S.  pedrofrsantos@gmail.
com), Hospital de Santa Maria, Lisbon, Portugal; the Department 
of Radiology (T.M.C.), Instituto Português de Oncologia de Lisboa 
Francisco Gentil, Lisbon, Portugal.
Received 4 March 2014, revision requested 27 April 2014, revision received 
3 June 2014, accepted 8 July 2014.
Published online 28 October 2014.
DOI 10.5152/dir.2014.14053
4
Uterine sarcomas • 5
Leiomyosarcoma
Clinical features
Leiomyosarcoma is the most com-
mon histological subtype of uterine 
sarcomas. The great majority arise de 
novo, but rarely (in 0.2% of cases) it 
may result from a sarcomatous trans-
formation in a benign leiomyoma (2). 
It is characterized by an aggressive 
behavior (even when confined to the 
uterus), with a five-year survival rate 
ranging from 18.8% to 68%, which 
varies widely according to different 
stages. Low-grade and serosal involve-
ment seem to be significant prognostic 
factors. The reported risk of recurrence 
varies from 45% to 73% (1, 6, 8). 
Most leiomyosarcomas occur in 
women over 40 years of age, with a 
median age of 60 years. There is a two-
fold incidence of leiomyosarcoma in 
African-American women; long-term 
tamoxifen use and prior pelvic radia-
tion seem to be associated with a small 
increase in risk (4). Signs and symp-
toms are similar to those occurring 
with leiomyomas, and include abnor-
mal vaginal bleeding (56%), palpable 
pelvic mass (54%) and pelvic pain 
(22%). Less frequently, they can pres-
ent as hemoperitoneum (due to tumor 
rupture), or symptoms resulting from 
extra-uterine extension or metasta-
ses (8). Besides that, although “rapid 
growth” of a presumed leiomyoma is 
considered a suspicious finding, the 
definition of the latter remains contro-
versial. Therefore, preoperative distinc-
tion between benign leiomyomas and 
malignant leiomyosarcomas is very 
difficult (if not impossible) based sole-
ly on clinical features, and remains a 
challenge for clinicians (1, 8).
MRI features
Leiomyosarcomas are often difficult 
to differentiate from leiomyomas (the 
most common myometrial tumor), 
based on clinical features and even en-
dometrial biopsy or dilatation and frac-
tional curettage. Furthermore, recent 
advances in leiomyoma management 
(i.e., development of uterus-preserving 
treatments, such as gonadotropin-re-
leasing hormone analogues, uterine 
arterial embolization, and focused ul-
trasound surgery) have significantly 
raised the importance of pretreatment 
imaging diagnosis of uterine sarcomas 
(3, 9, 10). 
On MRI, leiomyosarcomas com-
monly manifest as large infiltrating 
myometrial mass of heterogeneous 
hypointensity on T1-weighted images, 
with irregular and ill-defined margins. 
On T2-weighted images, they usually 
show intermediate-to-high signal in-
tensity, with central hyperintensity in-
dicative of extensive necrosis (present 
in >50% of cases) (Fig. 1a, 1b). Hemor-
rhage is common, and foci of calcifi-
cations may be present. After contrast 
administration, they present early het-
erogeneous enhancement, due to the 
aforementioned areas of necrosis and 
hemorrhage (Fig. 1c) (1–3, 10, 11). 
Leiomyosarcomas are generally larg-
er and show more rapid growth than 
leiomyomas (3). On the other hand, 
common benign leiomyomas can 
show areas of increased signal intensi-
ty on T2-weighted images as well, due 
to various types of degeneration or cel-
lular histologic subtypes (9, 10). Some 
authors have suggested the presence of 
irregular margins, necrosis, and rapid 
growth as the most suggestive features 
of malignancy (2).
Diffusion-weighted imaging (DWI) 
has the potential to delineate malig-
nant lesions as hyperintense areas with 
excellent tissue contrast, providing 
quantitative measurements of apparent 
diffusion coefficient (ADC) values (Fig. 
2). Tamai et al. (10) reported significant 
differences in mean ADC values of leio-
Table 1. Staging for uterine leiomyosarcoma (7) 
Stage  Definition
I  Tumor limited to uterus
 IA <5 cm
 IB >5 cm
II  Tumor extends beyond the uterus, within the pelvis
 IIA Adnexal involvement
 IIB Involvement of other pelvic tissues
III  Tumor invades abdominal tissues (not just protruding into the abdomen)
 IIIA One site
 IIIB More than one site
 IIIC Metastasis to pelvic and/or para-aortic lymph nodes
IV IVA Tumor invades bladder and/or rectum
 IVB Distant metastasis
Table 2. Staging for uterine endometrial stromal sarcoma and adenosarcoma (7) 
Stage  Definition
I  Tumor limited to uterus
 IA Tumor limited to endometrium/endocervix with no myometrial invasion
 IB Less than half or half myometrial invasion
 IC More than half myometrial invasion
II  Tumor extends beyond the uterus, within the pelvis
 IIA Adnexal involvement
 IIB Involvement of other pelvic tissues
III  Tumor invades abdominal tissues (not just protruding into the abdomen)
 IIIA One site
 IIIB More than one site
 IIIC Metastasis to pelvic and/or para-aortic lymph nodes
IV IVA Tumor invades bladder and/or rectum
 IVB Distant metastasis
myosarcomas, compared with normal 
myometrium and degenerated leiomy-
omas, without any overlap. Namimoto 
et al. (9) showed that overlap in ADC 
values between leiomyosarcomas and 
ordinary leiomyomas (attributed to the 
“T2 blackout effect,” i.e., hypointensi-
ty on DWI caused by hypointensity on 
T2-weighted images) could be resolved 
with the evaluation of tumor-myome-
trium contrast ratio on T2-weighted 
images. Thomassin-Naggara et al. (12) 
reported that by combining the analy-
sis of T2 signal intensity, b1000 images 
and ADC map, MRI achieved 92.4% 
accuracy in distinguishing benign and 
uncertain or malignant myometrial tu-
mors. Therefore, they concluded that 
DWI may limit misdiagnosis of uterine 
sarcomas as benign leiomyomas, and 
should be the first criterion to help ra-
diologists characterize a unique uterine 
tumor. Based on these results, the use 
of DWI must be recommended in the 
setting of myometrial lesions, especial-




According to the World Health Orga-
nization classification, an endometrial 
stromal tumor is composed of cells that 
resemble endometrial stromal cells of 
the proliferative endometrium (13). ESS 
corresponds to the former “low-grade 
ESS”, and UES replaces the term “high-
grade ESS”. This new classification is a 
result of the recognition of the very dis-
tinct biological behaviors and clinical 
outcomes of these tumors (3, 4, 6, 8).
ESS is a rare tumor, accounting for 
0.2% of all malignant uterine tumors 
and 10%–15% of uterine malignancies 
with a mesenchymal component (3, 6, 
8). It is considered to be a low-grade, 
well-differentiated tumor without sig-
nificant cellular atypia (4). ESS is there-
fore a relatively indolent lesion, gen-
erally with a favorable prognosis, with 
five- and 10-year survival rates of 98% 
and 89% for stage I disease, which cor-
responds to the majority of patients at 
presentation (3, 8). However, the out-
come is largely dependent on the extent 
of the tumor at presentation, and stage 
seems to be the most significant indica-
tor for survival (3, 6, 8). For stages II and 
III, five-year survival significantly drops 
to 50% and 65%, respectively (3). ESS 
is also characterized by late recurrences 
(14%–60% of patients), even in patients 
with stage I disease (6, 8). Therefore, 
long-term follow-up is mandatory.
ESS occurs more commonly in wom-
en between 40 and 55 years of age (8). 
There has been a reported association 
with tamoxifen and estrogen use, al-
though data are limited (3, 14). They 
usually present with abnormal vaginal 
bleeding, pelvic pain, and dismenor-
rhea; however, as many as 25% of pa-
tients are asymptomatic (1, 3, 8). 
According to the new FIGO staging 
for uterine sarcomas, ESS is staged in the 
same manner as adenosarcoma (Table 2). 
MRI features
Imaging (and particularly MRI) may 
be a powerful tool in the management 
of these tumors, allowing characteriza-
tion of the initial stage and also pro-
viding differentiation from the more 
common endometrial carcinoma (3). 
ESS more frequently appears as pol-
ypoid endometrial mass, with low sig-
nal on T1-weighted images and heter-
ogeneously increased high T2 signal 
(3, 11, 15). It typically shows myo-
metrial involvement, either sharply 
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Figure 1. a–c. Leiomyosarcoma in a 52-year-old woman. Sagittal T1-weighted image (a), T2-weighted image (b), and gadolinium-enhanced T1-
weighted image with fat suppression (c) show marked uterine enlargement due to a heterogeneous myometrial tumor. The lesion demonstrates 
central hyperintensity on T1-weighted image (a) attributable to extensive hemorrhage, a central area of high signal on T2-weighted image (b) 
representing cystic necrosis, and early intense enhancement in solid areas of the tumor (c, arrow), as compared with normal myometrium. Irregular 
central zones of low signal intensity (asterisk) suggest extensive tumor necrosis. Endometrial cavity is pushed anteriorly by the tumor (b, arrow). 
a b c
Figure 2. a, b. Leiomyosarcoma in a 54-year-old woman. Axial DWI on b1000 (a) demonstrates 
a hyperintense mass. The mass appears hypointense on ADC map (b, asterisk), with the normal 
myometrium seen as an area of hyperintensity (arrows). 
a b
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demarcated or in a more diffuse and 
destructive manner (the latter is far 
more common with UES) (Fig. 3a). 
These tumors have a tendency for lym-
phatic and vascular invasion, showing 
worm-like extension bands of low sig-
nal intensity within areas of myome-
trial involvement on T2-weighted im-
ages (“bag of worms”), corresponding 
to preserved bundles of myometrium 
(Fig. 4) (2, 3, 11, 15–17). After contrast 
administration, enhancement is mod-
erate and commonly heterogeneous 
(Fig. 3b) (3, 15).
Compared to endometrial carcino-
ma, ESS usually shows larger size, more 
contrast enhancement, irregular mar-
gin, nodular extension into the myo-
metrium, and marginal nodularity due 
to tumor extension along vessels and 
lymphatics (2, 3, 15, 16).
Rarely, ESS can appear as a myome-
trial mass mimicking intramural leio-
myoma with cystic degeneration. In 
these cases, intramyometrial ESS can 
be differentiated based on their rapid 
and invasive growth, lower degree of 
enhancement, lymphatic and vascu-
lar invasion, higher incidence of ne-
crosis, peripheral hypointense rim on 
T2-weighted images, and enhanced 
marginal irregularity (3, 11, 15, 18).
Lymph node metastases are seen in 
10% of patients, being more frequent 
locally within the pelvis or vagina, fol-
lowed by the lung parenchyma (3).
Undifferentiated endometrial sarcoma
Clinical features
UES, previously referred to as “high-
grade ESS”, is an aggressive tumor lack-
ing specific differentiation, and show-
ing no endometrial stromal features. 
It is characterized by myometrial in-
vasion, severe nuclear polymorphism, 
high mitotic activity, and/or tumor 
cell necrosis (4, 8). UES shows an ag-
gressive behavior, with five-year sur-
vival rates of 25%–55% (6). The most 
significant prognostic factor seems to 
be the presence of vascular invasion, 
decreasing five-year survival to as low 
as 17% (19). Local recurrences and dis-
tant metastases (due to hematogenous 
spread) are also associated with high 
mortality and poor outcome (8, 14). 
UES tends to occur in an older age 
group, when compared to ESS, with 
a mean age of 61 years at the time of 
diagnosis (2, 11). Signs and symptoms 
resemble those of leiomyosarcoma and 
include vaginal bleeding, palpable pel-
vic mass, and pelvic pain (16).
MRI features
UES typically appears as a large pol-
ypoid mass in an expanded endome-
trial cavity, showing heterogeneous 
signal intensity on both T1- and 
T2-weighted images (Fig. 5a). The lat-
ter is attributable to the high frequen-
cy of hemorrhage and necrosis within 
the tumor (11, 14, 17). UES tends to 
infiltrate the myometrium in a more 
destructive and extensive manner 
than ESS, due to marked vascular and 
lymphatic invasion (3, 11). Contrast 
enhancement is generally heteroge-
neous, and iso- or hyperintense when 
compared with normal myometrium, 
allowing differentiation from endo-
metrial carcinoma (Fig. 5b). Hyperen-
hancement, the presence of irregular 
margins, multiple marginal tumor 
nodules, intramyometrial worm-like 
extension, and multiple nodular mass 
formation, are more frequently seen in 
UES than ESS (2, 3, 15).
Adenosarcoma
Clinical features
Adenosarcoma is a rare uterine ma-
lignancy, accounting for 5.5%–9% of 
all uterine sarcomas (6). It is a mixed 
tumor, composed of a benign (but oc-
casionally atypical) epithelial compo-
Figure 3. a, b. Endometrial stromal sarcoma in an 82-year-old woman. Sagittal T2-weighted image 
(a) and sagital T1-weighted image with fat suppression, after contrast administration (b) show a 
very large lesion centered at cervix region, infiltrating uterine body superiorly and superior half of 
the vagina inferiorly. The tumor shows multiple foci of hyperintense signal on T2-weighted image 
due to extensive necrosis, as well as moderate and mildly heterogeneous contrast enhancement.  
a b
Figure 4. a, b. Sagittal (a) and axial (b) T2-weighted images show an endometrial stromal 
sarcoma in a 64-year-old woman. The lesion shows heterogeneous signal with extensive nodular 
invasion into the myometrium and marked marginal irregularity and nodularity (attributable to 
tumor extension along vessels and lymphatics).
a b
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nent, and a malignant stromal (sarco-
matous, usually low-grade) element (4, 
6, 16). Adenosarcoma is considered a 
mixed Müllerian tumor, intermediate 
between adenofibroma and carcinosar-
coma; it was even suggested that some 
adenofibromas are in fact well-differ-
entiated adenosarcomas (3, 6, 8). It is 
a slow-growing tumor, with low ma-
lignant potential and good prognosis. 
Majority of women are diagnosed at 
stage I (>60%), with an overall five-year 
survival over 80% (3, 4, 6). More than 
70% of adenosarcomas occur in the en-
dometrium, but they can also be found 
in the myometrium (probably from ad-
enomyosis), cervix, and extra-uterine 
tissues such as the ovaries. Extra-uter-
ine location is more common in adoles-
cents and young women (6, 8). 
Adenosarcoma with sarcomatous 
overgrowth is defined as an adenos-
arcoma with the sarcomatous com-
ponent constituting more than 25% 
of the tumor; it occurs in 8%–54% of 
uterine adenosarcomas, and 30% of 
ovarian adenosarcomas. It carries a 
worse prognosis, with mortality reach-
ing 50% at five years. Other proposed 
factors associated with a poorer out-
come and higher risk of recurrence are 
advanced age, myometrial invasion 
(found in 15% of cases), and lympho-
vascular extension (3, 4, 6, 8, 16). Late 
recurrence can be seen in one-third 
of the women at five years, therefore, 
long-term imaging follow-up is man-
datory (3).
Adenosarcoma most commonly 
presents with abnormal vaginal bleed-
ing; some women also complain of 
pelvic pain, palpable pelvic mass, or 
vaginal discharge (8).
According to the new FIGO staging for 
uterine sarcomas, adenosarcoma is staged 
in the same manner as ESS (Table 2). 
MRI features
Adenosarcoma is typically seen as a 
large well-demarcated polypoid mass 
arising within the endometrial cavity 
and protruding through the cervical 
os, causing marked enlargement of the 
uterus with a thin myometrium (3, 20, 
21). This polypoid mass usually shows 
a multiseptated cystic appearance, 
with multiple heterogeneous solid 
components that fill the endometrial 
cavity, and may mimic the appearance 
of gestational trophoblastic disease 
(Fig. 6a) (3, 20). On T2-weighted imag-
es, small hyperintense foci may be seen 
scattered within the mass, representing 
glandular epithelial components or ne-
crosis (8, 22). After administration of 
gadolinium, there is heterogeneous en-
hancement, with solid components of 
the mass showing enhancement simi-
lar to that of the myometrium (Fig. 6b) 
(3, 20, 21). 
Adenosarcoma with sarcomatous 
overgrowth may present with myome-
trial invasion and areas of hemorrhage 
and necrosis. However, on DWI, they 
usually show relatively low signal in-
tensity on high b-value, reflecting its 
low grade nature (21, 22).
Conclusion
Uterine sarcomas are a rare and ag-
gressive heterogeneous group of tumors 
of mesenchymal origin, with nonspe-
cific clinical features. MRI is useful in 
lesion detection and characterization, 
as well as assessment of disease stag-
ing. Although the radiologic findings of 
these lesions can overlap, characteristic 
features (summarized in Table 3) can 
help narrow the differential diagnosis 
and guide adequate treatment selection 
and follow-up. In addition to morpho-
logical features, DWI seems to be a po-
tentially useful tool in characterization 
of large uterine lesions.
Figure 5. a, b. Undifferentiated endometrial sarcoma in a 36-year-old woman. Sagittal T2-
weighted image (a) and T1-weighted image after gadolinium administration (b) show marked 
uterine enlargement due to a large polypoid heterogeneous tumor, with some nodular marginality 
(arrow). The lesion shows intense and heterogeneous contrast uptake (uncommon for endometrial 
carcinoma), with a hypointense area (asterisk) suggestive of necrosis.
a b
Figure 6. a, b. Adenosarcoma in a 76-year-old woman. Sagittal T2-weighted image (a) and 
oblique coronal T1-weighted image with fat suppression, after contrast administration (b) show a 
very large polypoid mass with heterogeneous high signal intensity arising within the endometrial 
cavity and protruding into the cervical os (arrow), causing marked enlargement of the uterus. 
The tumor demonstrates a multicystic appearance (asterisk), with solid areas demonstrating 
enhancement similar to myometrium. 
a b
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Table 3. MRI features of uterine sarcomas, leiomyoma, and endometrial carcinoma  
 LMS ESS UES AS Leiomyoma Endometrial carcinoma
Localization Myometrium Generally  Generally Endometrium Myometrium Endometrium 
  endometrium;  endometrium; 
  can be located  can be located 
  in myometrium in myometrium   
Margins Irregular and  Irregular and Markedly irregular Regular and well Regular Regular or irregular 
 ill-defined nodular and nodular demarcated  
T1 signal Hypointense and  Hypointense Heterogeneous Predominantly Low-to-intermediate Hypo-to-isointense signal 
 heterogeneous    hypointense, signal; high signal to normal endometrium 
 (hemorrhage,    heterogeneous foci – hemorrhagic 
 calcifications)     degeneration 
T2 signal Intermediate-to- Hyperintense Heterogeneous Multiseptated Low signal Hyperintense and 
 high signal and heterogenous;  (extensive cystic appearance; (non-degenerated); heterogeneous relative to 
  bands of low signal  hemorrhage and can show multiple high signal – cystic, normal endometrium 
  corresponding to  necrosis) small hyperintense myxoid degeneration 
  preserved   foci  
  myometrium    
Contrast  Early and Moderate (more Marked (generally Marked (generally Variable Hypointense compared 
enhancement heterogenous intense than  more intense than isointense compared  to normal myometrium 
  endometrial  normal to normal 
  carcinoma) and  myometrium) and myometrium) and 
  heterogeneous heterogeneous heterogeneous  
DWI Generally more  High signal and High signal and Low signal Variable; generally High signal and low 
 restriction (lower  low ADC low ADC (low grade nature) higher ADC values ADC 
 ADC values) than     than LMS 
 leiomyomas     
LMS, leiomyosarcoma; ESS, endometrial stromal sarcoma; UES, undifferentiated endometrial sarcoma; AS, adenosarcoma; DWI, diffusion-weighted imaging; 
ADC, apparent diffusion coefficient.
